Last reviewed · How we verify
Diethylcarbamazine on day 1
Diethylcarbamazine immobilizes and kills microfilariae by interfering with their neuromuscular function, making them susceptible to immune clearance.
Diethylcarbamazine immobilizes and kills microfilariae by interfering with their neuromuscular function, making them susceptible to immune clearance. Used for Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi infection), Loiasis (Loa loa infection), Onchocerciasis (as adjunctive therapy).
At a glance
| Generic name | Diethylcarbamazine on day 1 |
|---|---|
| Also known as | DEC-d1, Banocide |
| Sponsor | Lihir Medical Centre |
| Drug class | Microfilaricide |
| Target | Microfilarial neuromuscular system |
| Modality | Small molecule |
| Therapeutic area | Parasitic Infection / Tropical Medicine |
| Phase | Phase 3 |
Mechanism of action
Diethylcarbamazine (DEC) is a microfilaricide that acts on the nervous system of microfilariae, causing paralysis and death. It enhances the host immune response against the parasites, facilitating their removal by macrophages and other immune cells. The drug is particularly effective against Wuchereria bancrofti, Brugia malayi, and Loa loa microfilariae.
Approved indications
- Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi infection)
- Loiasis (Loa loa infection)
- Onchocerciasis (as adjunctive therapy)
Common side effects
- Headache
- Nausea and vomiting
- Abdominal pain
- Fever
- Allergic reactions (due to parasite death)
- Dizziness
Key clinical trials
- Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji (NA)
- Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diethylcarbamazine on day 1 CI brief — competitive landscape report
- Diethylcarbamazine on day 1 updates RSS · CI watch RSS
- Lihir Medical Centre portfolio CI